Cramer Rosenthal Mcglynn LLC Sells 2,585 Shares of Cooper Companies Inc (NYSE:COO)
Cramer Rosenthal Mcglynn LLC decreased its position in Cooper Companies Inc (NYSE:COO) by 2.8% during the second quarter, HoldingsChannel.com reports. The fund owned 88,519 shares of the medical device company’s stock after selling 2,585 shares during the quarter. Cramer Rosenthal Mcglynn LLC’s holdings in Cooper Companies were worth $29,821,000 at the end of the most recent reporting period.
A number of other large investors have also recently added to or reduced their stakes in the business. BlackRock Inc. increased its position in shares of Cooper Companies by 1.4% during the 1st quarter. BlackRock Inc. now owns 3,784,211 shares of the medical device company’s stock valued at $1,120,769,000 after purchasing an additional 51,482 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Cooper Companies by 9.7% during the fourth quarter. Geode Capital Management LLC now owns 721,796 shares of the medical device company’s stock valued at $183,414,000 after acquiring an additional 63,889 shares during the period. Northern Trust Corp increased its stake in shares of Cooper Companies by 2.4% during the first quarter. Northern Trust Corp now owns 602,699 shares of the medical device company’s stock valued at $178,501,000 after acquiring an additional 14,293 shares during the period. WCM Investment Management LLC grew its position in Cooper Companies by 0.6% in the first quarter. WCM Investment Management LLC now owns 535,205 shares of the medical device company’s stock worth $158,512,000 after buying an additional 3,352 shares during the last quarter. Finally, Champlain Investment Partners LLC grew its position in Cooper Companies by 0.3% in the first quarter. Champlain Investment Partners LLC now owns 390,720 shares of the medical device company’s stock worth $115,720,000 after buying an additional 1,210 shares during the last quarter. 96.00% of the stock is currently owned by institutional investors and hedge funds.
COO has been the topic of several recent research reports. Raymond James restated a “buy” rating on shares of Cooper Companies in a research report on Monday, August 26th. Northcoast Research reaffirmed a “buy” rating and issued a $340.00 price objective (up previously from $331.00) on shares of Cooper Companies in a research note on Monday, June 3rd. ValuEngine lowered shares of Cooper Companies from a “buy” rating to a “hold” rating in a research note on Tuesday. Zacks Investment Research raised shares of Cooper Companies from a “hold” rating to a “buy” rating and set a $336.00 price objective for the company in a research note on Friday, June 7th. Finally, Piper Jaffray Companies set a $360.00 price objective on shares of Cooper Companies and gave the stock a “buy” rating in a research note on Friday, August 30th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company. Cooper Companies presently has an average rating of “Buy” and a consensus price target of $326.27.
NYSE:COO traded down $0.05 during mid-day trading on Friday, hitting $304.95. 1,949 shares of the company’s stock were exchanged, compared to its average volume of 322,884. The company has a current ratio of 1.29, a quick ratio of 0.73 and a debt-to-equity ratio of 0.39. Cooper Companies Inc has a fifty-two week low of $228.65 and a fifty-two week high of $344.32. The company has a 50 day simple moving average of $325.48 and a 200-day simple moving average of $308.99. The firm has a market capitalization of $14.72 billion, a P/E ratio of 26.52, a PEG ratio of 2.24 and a beta of 0.93.
Cooper Companies (NYSE:COO) last announced its quarterly earnings results on Thursday, August 29th. The medical device company reported $3.23 EPS for the quarter, beating the Zacks’ consensus estimate of $3.16 by $0.07. The business had revenue of $679.40 million during the quarter, compared to analyst estimates of $687.60 million. Cooper Companies had a net margin of 17.08% and a return on equity of 17.15%. Cooper Companies’s quarterly revenue was up 2.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.00 EPS. As a group, analysts expect that Cooper Companies Inc will post 12.32 earnings per share for the current year.
About Cooper Companies
The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.
Featured Article: Holder of Record
Want to see what other hedge funds are holding COO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cooper Companies Inc (NYSE:COO).
Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.